ArticleCancer medicine2026
Epidemiology of Colorectal Cancer in French Guiana From 2003 to 2017.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a major global public health issue, with 1.9 million new cases and 904,000 deaths in 2022. French Guiana is an overseas territory located in the Amazon region with many unique features, but data on CRC in this area remains limited. The objective of this work was to evaluate the prognosis of CRC and the associated factors in French Guiana.
methodsWe used the French Guiana Cancer Registry database for the period 2003 to 2017. A survival analysis was conducted. Additionally, standardized incidence and mortality rates were calculated and mapped using QGIS.
resultsDuring this period, 457 patients were included, with a male predominance (54.7%). The median age was 62 years. One-third of the population was born abroad. The 5-year overall survival rate was 47.4% (95% CI [42.1-53.5]). Female sex was associated with better 5-year survival: 55% [47.2-64.0] vs. 41% [35.0-50.0] for males (p = 0.03). In the multivariate analysis, sex and place of birth were independently associated with overall survival (HR = 0.7 [0.5-0.9], p = 0.002 for females; HR = 1.5 [1.1-2.1], p = 0.005 for those born abroad). The age-standardized incidence rate, adjusted to the world population, was 22.6 per 100,000 in men and 17.2 per 100,000 in women. Standardized mortality was 14 per 100,000 for men and 8.5 per 100,000 for women.
conclusionIn French Guiana, the 5-year survival rate for CRC was lower than in mainland France. Being born abroad was associated with poorer survival, reflecting health inequalities linked to socio-economic vulnerability in this territory, despite a lower overall incidence of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.